Outcome (deaths unrelated to CML progression censored). Censoring the deaths unrelated to CML progression (in CP and in CHR at the time of death), no difference was observed in the outcome between older and younger patients. FFS and PFS were calculated, censoring deaths unrelated to CML progression, from the date of the first IM dose until failure or death (FFS), and progression to AP/BP or death (PFS). *Failures (updated European LeukemiaNet recommendations²⁵ ) indicate no CHR at 3 months, no CyR at 6 months, < PCyR at 12 months, < CCyR at 18 months, loss of CHR or CCyR or progression to AP/BP, occurrence of CCA/Ph⁺, and occurrence of mutation poorly sensitive to IM at any time. Deaths indicate deaths resulting from CML progression (other deaths censored). †Progressions indicate progressions to AB/BP. Deaths indicate deaths resulting from CML progression (other deaths censored).